Welcome to our dedicated page for CERo Therapeutics news (Ticker: CERO), a resource for investors and traders seeking the latest updates and insights on CERo Therapeutics stock.
CERo Therapeutics Holdings, Inc. (CERO) is a biotechnology company developing engineered T cell immunotherapies for cancer, with a focus on its CER-T (Chimeric Engulfment Receptor T cell) platform and lead candidate CER-1236. The CERO news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how this clinical-stage program is progressing.
News about CERo frequently centers on clinical trial milestones for CER-1236, including updates from the ongoing first-in-human, multi-center, open-label Phase 1/1b trial known as CertainT-1. Articles describe cohort initiations, completion of dose-limiting toxicity observation periods, dose escalation decisions, and early safety and pharmacokinetic observations in patients with acute myeloid leukemia and related bone marrow diseases such as myelodysplastic syndrome and myelofibrosis.
Investors and observers can also expect regulatory and scientific conference updates, such as announcements of data presentations at meetings like the Society for Immunotherapy of Cancer, where CERo has highlighted preclinical data on sustained cell expansion and cytokine responses for CER-1236. These items provide context on how the company’s CER-T platform is being evaluated by the scientific and medical community.
Another recurring theme in CERO news is capital markets and listing status. The company has issued releases about its transition from Nasdaq to OTC Markets, including listings on OTC PINK and OTCQB, and about financing arrangements involving convertible preferred stock and equity purchase agreements. These updates outline how CERo is seeking to fund its research and maintain access to public markets.
By reviewing the CERO news page, readers can track clinical development steps, financing transactions, listing developments, and corporate communications that shape the outlook for CERo’s engineered T cell immunotherapy programs over time.
CERo Therapeutics (Nasdaq: CERO) reported investigators administered a third infusion of CER-1236 (1 million cells/kg) to a patient in Cohort One of its Phase 1 trial, completed about one week ago and matching the first two doses.
The third infusion precedes first dosing in Cohort Two, anticipated in coming weeks pending regulatory notifications. The company completed the first tranche (~$2.3 million) of a planned $7 million financing to extend cash runway and support Nasdaq compliance. The trial is ongoing; no CER-1236–attributable toxicities observed in the first three patients to date, and no safety or efficacy conclusions are being made yet.
CERo Therapeutics (Nasdaq: CERO) announced that CEO Chris Ehrlich will participate on a stem cell therapy panel titled “A Space That is Ready to Have its Day” at the Maxim Growth Summit on October 22, 2025 in New York City.
The Summit runs October 22–23, 2025 at the Hard Rock Hotel; the panel is scheduled for 1:30pm ET on October 22. A live webcast will be available on the company’s investor relations site, and a replay will be archived for 90 days. Mr. Ehrlich will be available for one-on-one meetings during the conference.
CERo Therapeutics (Nasdaq: CERO) announced on October 13, 2025 that it completed Cohort 1 of its first-in-human Phase 1/1b study of CER-1236 in acute myeloid leukemia (AML).
The company reported in-vivo cell expansion consistent with preclinical expectations and no dose-limiting toxicities (DLTs) in Cohort 1. The Dose Escalation Safety Committee approved initiation of Cohort 2, where three new patients will receive an increased starting dose pending regulatory approval.
CERo plans an additional infusion for the second Cohort 1 subject to explore multiple-infusion dosing versus single higher doses and said it is not currently pursuing acquisitions or partnerships while dose finding continues.
CERo Therapeutics (Nasdaq: CERO) has reached a milestone in its Phase 1 clinical trial of CER-1236 for acute myeloid leukemia (AML) with the dosing of the third patient in the initial dose cohort. The first-in-human, multi-center study aims to evaluate the safety, tolerability, and preliminary activity of CER-1236 in patients with various forms of AML.
The trial consists of two parts: dose escalation to establish a recommended Phase 2 dose, followed by an expansion phase. The protocol has been modified to allow for a second infusion in the same subject within each cohort. Initial pharmacokinetic data has shown cell expansion at the lowest dose level.
Primary outcome measures include monitoring adverse events, dose-limiting toxicities, and anti-leukemic activity through metrics such as overall response rate and complete response rates.
CERo Therapeutics (NASDAQ:CERO) has received a Notice of Allowance from the U.S. Patent and Trademark Office for its Application 19/019,111, providing composition of matter and method of use protection for CER-1236 through 2041. The patent will offer comprehensive protection for their cancer treatment compound.
The company also secured a patent in Japan for its CER platform, bringing their total intellectual property portfolio to 18 patents and 2 allowed applications internationally. This strengthens CERo's position, complementing their recent FDA Fast Track and Orphan Drug Designations, while they continue to progress with their Phase 1 clinical trial.
CERo Therapeutics (NASDAQ:CERO) has announced a significant modification to its Phase 1 clinical trial of CER-1236 for acute myeloid leukemia (AML). The company has received IRB approval to implement dose intensification, effectively doubling the cell product infusion amount following encouraging pharmacokinetic data showing cell expansion in the first two patients.
The trial, known as CertainT-1, is evaluating CER-1236, an autologous chimeric engulfment receptor T-cell therapy. The study design includes a two-part Phase 1/1b trial focusing on patients with relapsed/refractory AML, those in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS/AML.
CERo Therapeutics (NASDAQ:CERO) has received Fast Track Designation from the FDA for its lead compound CER-1236 in treating Acute Myeloid Leukemia (AML). This designation, complementing its existing Orphan Drug Designation, aims to accelerate development and review of the therapy.
The company is currently conducting a Phase 1/1b first-in-human study evaluating CER-1236's safety and preliminary efficacy in multiple AML patient groups. The trial includes dose escalation to determine optimal dosing, followed by an expansion phase focusing on safety and efficacy measures including response rates and pharmacokinetics.
CERo Therapeutics (NASDAQ:CERO) has announced the dosing of the second patient in its Phase 1 clinical trial of CER-1236, a novel CAR-T therapy targeting TIM 4L for acute myeloid leukemia (AML). The treatment was administered at the Sarah Cannon Research Institute at Colorado Blood Cancer Institute.
The company reported promising data from the first patient, who showed no dose-limiting toxicities during the 28-day observation period. Notably, the therapy demonstrated a 20.8-fold expansion of infused cells, peaking at 14 days post-infusion.
The Phase 1/1b study aims to evaluate CER-1236's safety and efficacy in patients with relapsed/refractory AML, AML in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS/AML.